Administration of a probiotic with peanut oral immunotherapy: A randomized trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2015 Mar;135(3):737-44.e8.
doi: 10.1016/j.jaci.2014.11.034. Epub 2015 Jan 13.
Affiliations
- PMID: 25592987
- DOI: 10.1016/j.jaci.2014.11.034
Randomized Controlled Trial
Administration of a probiotic with peanut oral immunotherapy: A randomized trial
Mimi L K Tang et al. J Allergy Clin Immunol. 2015 Mar.
Abstract
Background: Coadministration of a bacterial adjuvant with oral immunotherapy (OIT) has been suggested as a potential treatment for food allergy.
Objective: To evaluate a combined therapy comprising a probiotic together with peanut OIT.
Methods: We performed a double-blind, placebo-controlled randomized trial of the probiotic Lactobacillus rhamnosus CGMCC 1.3724 and peanut OIT (probiotic and peanut oral immunotherapy [PPOIT]) in children (1-10 years) with peanut allergy. The primary outcome was induction of sustained unresponsiveness 2 to 5 weeks after discontinuation of treatment (referred to as possible sustained unresponsiveness). Secondary outcomes were desensitization, peanut skin prick test, and specific IgE and specific IgG4 measurements.
Results: Sixty-two children were randomized and stratified by age (≤5 and >5 years) and peanut skin test wheal size (≤10 and >10 mm); 56 reached the trial's end. Baseline demographics were similar across groups. Possible sustained unresponsiveness was achieved in 82.1% receiving PPOIT and 3.6% receiving placebo (P < .001). Nine children need to be treated for 7 to achieve sustained unresponsiveness (number needed to treat, 1.27; 95% CI, 1.06-1.59). Of the subjects, 89.7% receiving PPOIT and 7.1% receiving placebo were desensitized (P < .001). PPOIT was associated with reduced peanut skin prick test responses and peanut-specific IgE levels and increased peanut-specific IgG4 levels (all P < .001). PPOIT-treated participants reported a greater number of adverse events, mostly with maintenance home dosing.
Conclusion: This is the first randomized placebo-controlled trial evaluating the novel coadministration of a probiotic and peanut OIT and assessing sustained unresponsiveness in children with peanut allergy. PPOIT was effective in inducing possible sustained unresponsiveness and immune changes that suggest modulation of the peanut-specific immune response. Further work is required to confirm sustained unresponsiveness after a longer period of secondary peanut elimination and to clarify the relative contributions of probiotics versus OIT.
Keywords: Peanut allergy; desensitization; immune-modifying adjuvant; oral immunotherapy; peanut-specific IgE; peanut-specific IgG(4); probiotic; sustained unresponsiveness; tolerance.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Similar articles
- Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P, Orsini F, Lozinsky AC, Gold M, O'Sullivan MD, Quinn P, Lloyd M, Ashley SE, Pitkin S, Axelrad C, Metcalfe JR, Su EL, Tey D, Robinson MN, Allen KJ, Prescott SL, Galvin AD, Tang MLK; PPOIT-003 study group. Loke P, et al. Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4. Lancet Child Adolesc Health. 2022. PMID: 35123664 Clinical Trial. - Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).
Chebar Lozinsky A, Loke P, Orsini F, O'Sullivan M, L Prescott S, Gold MS, Quinn P, DunnGalvin A, Lk Tang M; PPOIT study team. Chebar Lozinsky A, et al. BMJ Open. 2020 Sep 9;10(9):e035871. doi: 10.1136/bmjopen-2019-035871. BMJ Open. 2020. PMID: 32912942 Free PMC article. - Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy.
Nozawa A, Okamoto Y, Movérare R, Borres MP, Kurihara K. Nozawa A, et al. Pediatr Allergy Immunol. 2014 Jun;25(4):323-8. doi: 10.1111/pai.12243. Pediatr Allergy Immunol. 2014. PMID: 24953293 Clinical Trial. - Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A. Nurmatov U, et al. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009014. doi: 10.1002/14651858.CD009014.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972130 Free PMC article. Review. - Peanut Oral Immunotherapy: State of the Art.
Tang MLK, Lozinsky AC, Loke P. Tang MLK, et al. Immunol Allergy Clin North Am. 2020 Feb;40(1):97-110. doi: 10.1016/j.iac.2019.09.005. Epub 2019 Nov 6. Immunol Allergy Clin North Am. 2020. PMID: 31761124 Review.
Cited by
- Targeting Food Allergy with Probiotics.
Carucci L, Coppola S, Carandente R, Canani RB. Carucci L, et al. Adv Exp Med Biol. 2024;1449:79-93. doi: 10.1007/978-3-031-58572-2_5. Adv Exp Med Biol. 2024. PMID: 39060732 Review. - A Review of Shared Decision-Making, Published Protocols, and Post-desensitization Strategies in Oral Immunotherapy (OIT).
Laubach S, Kim EH, Greenhawt M, Bailey S, Anagnostou A. Laubach S, et al. Curr Allergy Asthma Rep. 2024 Apr;24(4):173-197. doi: 10.1007/s11882-024-01132-2. Epub 2024 Mar 5. Curr Allergy Asthma Rep. 2024. PMID: 38441821 Free PMC article. Review. - The Future of Food Allergy Management: Advancements in Therapies.
Ezhuthachan ID, Beaudoin M, Nowak-Wegrzyn A, Vickery BP. Ezhuthachan ID, et al. Curr Allergy Asthma Rep. 2024 Apr;24(4):161-171. doi: 10.1007/s11882-024-01133-1. Epub 2024 Feb 23. Curr Allergy Asthma Rep. 2024. PMID: 38393624 Review. - Low-dose oral immunotherapy in immunoglobulin E-mediated food allergies.
Ma D, Zhu R. Ma D, et al. Front Immunol. 2024 Feb 1;15:1321863. doi: 10.3389/fimmu.2024.1321863. eCollection 2024. Front Immunol. 2024. PMID: 38361918 Free PMC article. Review. - Probiotics in Infancy and Childhood for Food Allergy Prevention and Treatment.
Di Costanzo M, Vella A, Infantino C, Morini R, Bruni S, Esposito S, Biasucci G. Di Costanzo M, et al. Nutrients. 2024 Jan 18;16(2):297. doi: 10.3390/nu16020297. Nutrients. 2024. PMID: 38257190 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources